

Curriculum Vitae

Personal information **Mark van Bussel**

Work experience

1. Employer: Medicines Evaluation Board
 - Start date: 2019
 - End date:
 - Position: Clinical Assessor
 - Activities: assessment of clinical trials and providing scientific advice
 - Country: Netherlands
2. Employer: The Netherlands Cancer Institute
 - Start date: 2015
 - End date: 2019
 - Position: PhD candidate / Clinical Pharmacologist in Training
 - Activities: clinical research
 - Country: Netherlands
3. Employer: VieCuri Medical Centre
 - Start date: 122013
 - End date: 122014
 - Position: Pharmacist
 - Activities: clinical services
 - Country: Netherlands

Education and training

1. Subject: Clinical pharmacology training
 - Start date: 2016
 - End date: 2019
 - Qualification: Clinical Pharmacologist
 - Organisation: The Netherlands Cancer Institute
 - Country: Netherlands
2. Subject: Clinical pharmacology of anticancer agents with focus on neuro-oncology and biomarker assessment
 - Start date: 2015
 - End date: 2019
 - Qualification: PhD
 - Organisation: Utrecht University
3. Subject: Pharmacy
 - Start date: 2007
 - End date: 2013
 - Qualification: PharmD
 - Organisation: Utrecht University
 - Country: Netherlands

Additional information

Publications

Maliepaard M, Faber YS, van Bussel MTJ. Reported hepatotoxicity and hepatotoxicity guidance in the product information of protein kinase inhibitors in oncology registered at the European Medicines Agency. *Pharmacol Res Perspect.* 2023 Apr;11(2):e01067.

Tabernero J, Van Cutsem E, Garralda E, Tai D, De Braud F, Geva R, van Bussel MTJ, Fiorella Dotti K, Elez E, de Miguel MJ, Litwiler K, Murphy D, Edwards M, Morris VK. A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer. *Oncologist.* 2023 Mar 17;28(3):230-238.

Maliepaard M, Carree W, van Bussel MTJ. Dose selection and tolerability of anticancer agents evaluated by the European Medicines Agency in the period 2015_2020. *ESMO Open.* 2021 Nov 6;6(6):100301.

van Bussel MTJ, Awada A, de Jonge MJA, Mau Sørensen M, Nielsen D, Schöffski P, Verheul HMW, Sarholz B, Berghoff K, El Bawab S, Kuipers M, Damstrup L, Diaz Padilla I, Schellens JHM. A first_in_man phase 1 study of the DNA_dependent protein kinase inhibitor pposertib (formerly M3814) in patients with advanced solid tumours. *Br J Cancer.* 2021 Feb;124(4):728_735.

van Bussel MTJ, Pluim D, Milojkovic Kerklaan B, Bol M, Sikorska K, Linders DTC, van den Broek D, Beijnen JH, Schellens JHM, Brandsma D. Circulating epithelial tumor cell analysis in CSF in patients with leptomeningeal metastases. *Neurology.* 2020 Feb 4;94(5):e521_e528.

van Bussel MTJ, Beijnen JH, Brandsma D. Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review. *BMC Cancer.* 2019 May 30;19(1):519

Pluim D, Ros W, van Bussel MTJ, Brandsma D, Beijnen JH, Schellens JHM. Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid. *J Pharm Biomed Anal.* 2019;164:128_134.

van Busse1 MTJ, Pluim D, Bol M, Beijnen JH, Schellens JHM, Brandsma D. EpCAM-based assays for epithelial tumor cell detection in cerebrospinal fluid. J Neuro-oncol. 2018;137(1):1-10.

Rood JJM, van Busse1 MTJ, Schellens JHM, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1031:80-85.

Projects

Memberships

Dutch Society for Clinical Pharmacology & Biopharmacy European Society for Medical Oncology

Other Relevant Information